A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer

BACKGROUND: Fulvestrant, a selective estrogen receptor degrader, is approved for first- and second-line treatment of postmenopausal women with hormone receptor-positive advanced breast cancer (ABC). METHODS: Meta-analysis of randomized controlled trials (RCTs) evaluating fulvestrant 500 mg in postme...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Breast Cancer
Autors principals: Robertson, John F. R., Jiang, Zefei, Di Leo, Angelo, Ohno, Shinji, Pritchard, Kathleen I., Ellis, Matthew, Bradbury, Ian, Campbell, Christine
Format: Artigo
Idioma:Inglês
Publicat: Springer Japan 2019
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6821663/
https://ncbi.nlm.nih.gov/pubmed/31079343
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12282-019-00973-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars